Megf9-KO Mouse
一般名
Megf9-KO
製品ID
S-KO-06324
背景情報
C57BL/6NCya
系統ID
KOCMP-230316-Megf9-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Megf9-KO Mouse(カタログ番号S-KO-06324)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Megf9-KO
系統ID
KOCMP-230316-Megf9-B6N-VA
遺伝子名
製品ID
S-KO-06324
遺伝子別名
Egfl5, mKIAA0818, 9630025C07, 4933405H16Rik
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conventional knockout
染色体
Chr 4
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000107359
NCBIトランスクリプトID
NM_172694
ターゲット領域
Exon 2
有効領域の大きさ
~0.2 kb
遺伝子研究の概要
MEGF9, a novel transmembrane protein with multiple EGF-like repeats, is predominantly expressed in the developing and adult central and peripheral nervous systems. It consists of an N-terminal region with potential O-glycosylation sites, five EGF-like domains homologous to laminins' short arms, a single-pass transmembrane domain, and a conserved intracellular domain with potential phosphorylation sites. It may function as a guidance or signalling molecule and is developmentally regulated [4].
In lipopolysaccharide (LPS)-induced cardiac dysfunction, MEGF9 expressions were reduced in cardiomyocytes, mice, and septic patients, and negatively correlated with cardiac dysfunction. MEGF9 overexpression attenuated, while knockdown aggravated LPS-induced inflammation and oxidative damage in vivo and in vitro, regulating cardiac injury. It alleviated LPS-induced cardiac dysfunction through activating the AMPK pathway [1]. In osteoarthritis, MEGF9 was a predicted target of miR-7. Upregulation of miR-7 or MEGF9 increased the expression of EGFR, MMP-13, and ADAMTS-5, aggravating cartilage degradation via activation of the PI3K/AKT/mTOR signalling pathway [2]. Mendelian randomization analysis showed MEGF9 was positively associated with male infertility in varicocele. Its expression increased in the varicocele model group and decreased after treatment with Bu Shen Huo Xue Prescription (BSHXP), suggesting BSHXP inhibiting MEGF9 may be a potential therapeutic target [3]. In neuropathic pain, MEGF9 was one of the candidate genes associated with microglial polarization, with higher expression in the NP model group compared to the sham group. In breast cancer, miR-125b, which was decreased in expression, performed its tumor-suppressor function via directly targeting MEGF9 [6]. In adolescent major depressive disorder, MEGF9 was identified as a hub gene in a module associated with stress, inflammation, and immune responses.
In summary, MEGF9 plays crucial roles in various biological processes and disease conditions. Studies, including those using in vivo models like LPS-treated mice, have revealed its significance in cardiac function, osteoarthritis, male infertility, neuropathic pain, breast cancer, and adolescent depression. These findings provide insights into potential therapeutic targets for these diseases.
References:
1. Jin, Zhili, Li, Xianqing, Liu, Huixia, Fan, Di, Wang, Hairong. 2024. MEGF9 prevents lipopolysaccharide-induced cardiac dysfunction through activating AMPK pathway. In Redox report : communications in free radical research, 30, 2435252. doi:10.1080/13510002.2024.2435252. https://pubmed.ncbi.nlm.nih.gov/39737911/
2. Jiang, Lifeng, Zhou, Xindie, Xu, Kai, Zhu, Junfeng, Wu, Lidong. . miR-7/EGFR/MEGF9 axis regulates cartilage degradation in osteoarthritis via PI3K/AKT/mTOR signaling pathway. In Bioengineered, 12, 8622-8634. doi:10.1080/21655979.2021.1988362. https://pubmed.ncbi.nlm.nih.gov/34629037/
3. Cai, Bin, Sun, Dalin, Deng, Weimin, Liu, Yuanyuan, Jin, Baofang. 2024. Mendelian randomization analysis and validation supports MEGF9 and MLLT11 as potential targets for the treatment of varicocele and male infertility. In Frontiers in endocrinology, 15, 1416384. doi:10.3389/fendo.2024.1416384. https://pubmed.ncbi.nlm.nih.gov/39391881/
4. Brandt-Bohne, Ulrike, Keene, Douglas R, White, Fletcher A, Koch, Manuel. . MEGF9: a novel transmembrane protein with a strong and developmentally regulated expression in the nervous system. In The Biochemical journal, 401, 447-57. doi:. https://pubmed.ncbi.nlm.nih.gov/16981854/
5. Gao, Sheng, Sun, Yuyan, Jia, Shu, Meng, Chunyang. 2024. Transcriptome analysis unveils PLSCR1 associated with microglial polarization in neuropathic pain. In Gene, 933, 148961. doi:10.1016/j.gene.2024.148961. https://pubmed.ncbi.nlm.nih.gov/39312982/
6. Feliciano, Andrea, Castellvi, Josep, Artero-Castro, Ana, Ramón Y Cajal, Santiago, Lleonart, Matilde E. 2013. miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. In PloS one, 8, e76247. doi:10.1371/journal.pone.0076247. https://pubmed.ncbi.nlm.nih.gov/24098452/
7. Zhao, Bao, Fan, Qingyue, Liu, Jintong, Wang, Pingping, Zhang, Wenxin. 2022. Identification of Key Modules and Genes Associated with Major Depressive Disorder in Adolescents. In Genes, 13, . doi:10.3390/genes13030464. https://pubmed.ncbi.nlm.nih.gov/35328018/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
